Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

AuthorsArana, Paula; Paiva, Bruno; Cedena, Maria-Teresa; Puig, Noemi; Cordón, Lourdes; Vidriales, Maria Belén; Gutiérrez, Norma Carmen; Chiodi, Francesca; Burgos, Leire; Anglada, Lucia-Lopez; Martínez-López, Joaquín; Hernandez, Miguel T.; Teruel, Ana-Isabel; Gironella, Mercedes; Echeveste, María-Asunción; Rosiñol, Laura; Martínez, Rafael; Oriol, Albert; Rubia, Javier de la; Orfao, Alberto CSIC ORCID ; Bladé, Joan; Lahuerta, Juan José; Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCID
Issue Date2018
PublisherNature Publishing Group
CitationLeukemia 32(4): 971-978 (2018)
AbstractPersistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19 pos, CD27 neg, CD38 lo, CD45 pos, CD81 pos, CD117 neg and CD138 lo expression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38 low CD81 pos CD117 neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients.
Publisher version (URL)
Identifiersdoi: 10.1038/leu.2017.320
e-issn: 1476-5551
issn: 0887-6924
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
progtrial.pdf131,06 kBAdobe PDFThumbnail
Show full item record
Review this work

PubMed Central

checked on May 18, 2022


checked on May 12, 2022


checked on May 13, 2022

Page view(s)

checked on May 18, 2022


checked on May 18, 2022

Google ScholarTM




Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.